Tyrosine kinase inhibitors imidazo [1,5-a] pyrazine.

A compound represented by formula I: or a pharmaceutically acceptable salt thereof, wherein: Q1 is aryl1, which is optionally substituted with one to five independent G1 substituents; R1 is alkyl, cycloalkyl, aryl, aralkyl or heterocyclyl, any of which is optionally substituted with one or more substituents independent G11; G1 is halo, -OR2, or - (X1) n- (Y1) m-R4; G41 is halo, -CF3, -OCF3, -OR2, -NR2R3 (R3a) j1, -CONR2R3, NR2 (C = O) R3, -S (C = O) OR2, C 0-10 alkyl or alkoxy C1-10- C2-10 alkenyl, any of which is optionally substituted with one or more halo, -OR222, - NR222R333 (R333a) J1A, -C (O) R222 or S (O) j1aR222; C 0-10 arylalkyl; or C 0-10 hetaryl-alkyl; G11 is halo, -OR21, -NR21R31 (R3a1) j4, -C (O) R21, -CO2R21, -CONR21R31, C 0-10 alkyl, C2-10 alkenyl, C1-10 alkoxy C1-10- alkyl, cycloalkyl C3- 8 or C 0-10 heterocyclyl-alkyl any of which is optionally substituted with one or more -OR2221, -NR2221R3331 (R333a1) j4a, -CONR2221R3331 or NR2221 (C = O) R3331 independent; or C 0-10 arylalkyl; R2, R3, R3a, R222, R333, R333a, R21, R31, R3a1, R2221, R3331 and R333a1 are each equal to C 0-10 alkyl, C3-8 cycloalkyl, heterocyclyl C 0-10 alkyl, aryl- C0 or C 0-10 hetaryl-10 alkyl; or in the case of NR2R3 (R3a) j1 or NR222R333 (R333a) J1A or -NR2221R3331 (R333a) j4a or R2 and R3 or R222 and R333 or R2221 and R3331 they may be taken together with the nitrogen atom to which they are attached to form a saturated ring, unsaturated ring, heterocyclic saturated ring or heterocyclic unsaturated ring 3-10 membered, wherein said ring is optionally substituted with one or more substituents G111; X1 and Y1 are each independently -O- or -CR5R6-; R5 and R6 are C 0-10 alkyl; G111 is alkyl C 0-10 or C 0-10 heterocyclyl-alkyl, any of which is optionally substituted with one or more halo, -OR77 or -NR77R87 independent; or C 0-10 arylalkyl; or C 0-10 hetaryl-alkyl; R4 is aryl, heteroaryl, cycloalkyl or heterocyclyl, any of which is optionally substituted with one or more substituents G41; R77 is each independently C 0-10 alkyl, which is optionally substituted with one or more hydroxy; n, m, j1, J1A are each independently equal to 0, 1 or 2; wherein alkyl is alkyl straight chain or branched selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, n- hexyl, n-heptyl, isooctyl, nonyl, decyl, undecyl, dodecyl, tetradecyl, hexadecyl, octadecyl and eicosyl; cycloalkyl is an aliphatic ring structure, aryl is phenyl or naphthyl; aryl 1 is phenyl; aralkyl is an alkyl group of straight or branched chain with an aryl moiety which forms a portion of the bridge aryl moiety alkyl; heterocyclyl is a saturated ring of 5 or 6 substituted or unsubstituted ring containing one, two or three heteroatoms selected from oxygen, nitrogen and sulfur or a bicyclic ring system containing up atoms including one heteroatom selected from oxygen, nitrogen and sulfur members wherein the ring containing the heteroatom is saturated; and heteroaryl is an unsaturated 5- or 6 substituted or unsubstituted containing one member, two, three or four heteroatoms selected from oxygen, nitrogen and sulfur or a system unsaturated bicyclic rings containing up to 10 atoms including one heteroatom selected from oxygen, nitrogen and sulfur